Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Alpha Mannosidosis Market Expected to Be in 2029?

The market size for alpha mannosidosis has expanded swiftly in the past years, set to increase from $15.1 billion in 2024 to $17.87 billion in 2025 with a compound annual growth rate (CAGR) of 18.3%. The notable growth in the previous period is linked to the growth of emerging markets, urbanization, a surge in demand for synthetic fibers, and governmental efforts to boost the textile industry.

In the ensuing years, the market size for alpha mannosidosis is projected to undergo swift expansion, with an expected enlargement to $33.81 billion in 2029, with a compound annual growth rate (CAGR) of 17.3%. The acceleration in the forecast period can be credited to factors such as global population expansion, urbanization, rising e-commerce, escalating demand for athletic clothing, growing penetration of organized retail in emerging economies, and escalated usage of social media. Key trends for the forecast period involve an upswing in enzyme therapy usage, adoption of hematopoietic stem cell transplantation, and the increasing usage of cisterna magna infusion.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp

What Are The Contributors To Demand In The Alpha Mannosidosis Market?

The alpha mannosidosis market is projected to grow due to the escalating demand for precision medicine. Precision medicine provides personalized healthcare, adjusting treatments based on individual genetic, environmental, and lifestyle factors. This surge in precision medicine is motivated by developments in genomic technologies and data analytics, permitting a more precise detection of genetic variants and their health effects. Moreover, the growing demand for tailored treatment alternatives, along with an increased understanding of the shortcomings of generic strategies, has sparked interest in customized healthcare solutions. Precision medicine assists in creating targeted therapies designed specifically for the unique genetic mutations and patient profiles associated with this unusual disorder. For instance, the U.S.-based nonprofit organization, the Personalized Medicine Coalition (PMC), revealed data in February 2024, which showed that the FDA approved 16 new personalized treatments for rare diseases in 2023, a significant rise from just six approvals the previous year. Thus, the escalating demand for precision medicine is bolstering the expansion of the alpha mannosidosis market.

The alpha mannosidosis market covered in this report is segmented –

1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies

2) By Indication: Type I, Type II, Type III

3) By End-User: Hospitals, Speciality Clinics

Subsegments:

1) By Bone Marrow Transplant (BMT): Autologous BMT, Allogeneic BMT

2) By Enzyme Replacement Therapy (ERT): Recombinant Enzymes, Long-acting Enzyme Formulations

3) By Other Therapies: Symptomatic Treatments, Gene Therapy, Supportive Care

What Are The Leading Trends And Opportunities In The Alpha Mannosidosis Sector?

Firms dominating the alpha mannosidosis market are channeling efforts into the creation of enzyme replacement therapy for this rare disease. This treatment brings the benefits of minimizing the build-up of mannose-rich oligosaccharides in different body tissues and organs, by providing exogenous alpha-mannosidase. Such build-up forms a typical aspect of alpha-mannosidosis, playing a role in its harmful effects. To illustrate, in February 2023, the US-based Chiesi Global Rare Diseases unveiled its product, Lamzede (velmanase alfa), the inaugural enzyme replacement therapy to gain authorization in the United States for addressing alpha-mannosidosis. This rare genetic illness is identified by a lack of alpha-mannosidase enzyme in the body, as well as its effects beyond the central nervous system. Lamzede operates similarly to the alpha-mannosidase enzyme naturally present in the human body, thereby restoring regular cellular functionality in patients. Patients are administered a 10 mg injection of Lamzede on a weekly basis.

Who Are The Top-Ranked Companies In The Alpha Mannosidosis Market Today?

Major companies operating in the alpha mannosidosis market include Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Merck, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd, Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma Plc, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bayer AG, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca plc, Biogen SA, Sanofi, Adcock Ingram

https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

How Is Alpha Mannosidosis Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the alpha mannosidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=4093&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model